Protein kinase CK2 controls T-cell polarization through dendritic cell activation in response to contact sensitizers

Archive ouverte

de Bourayne, Marie | Gallais, Yann | El Ali, Zeina | Rousseau, Philippe | Damiens, Marie-Hélène | Cochet, Claude | Filhol, Odile | Chollet-Martin, Sylvie | Pallardy, Marc | Kerdine-Römer, Saadia

Edité par CCSD ; Society for Leukocyte Biology -

International audience. Allergic contact dermatitis (ACD) represents a severe health problem with increasing worldwide prevalence. It is a T-cell-mediated inflammatory skin disease caused by chemicals present in the daily or professional environment. NiSO4 and 2,4-dinitrochlorobenzene (DNCB) are 2 chemicals involved in ACD. These contact sensitizers are known to induce an up-regulation of phenotypic markers and cytokine secretion in dendritic cells (DCs; professional APCs), leading to the generation of CD8+ Tc1/Tc17 and CD4+ Th1/Th17 effector T cells. In the present study, using a peptide array approach, we identified protein kinase CK2 as a novel kinase involved in the activation of human monocyte-derived DCs (MoDCs) in response to NiSO4 and DNCB. Inhibition of CK2 activity in MoDCs led to an altered mature phenotype with lower expression of CD54, PDL-1, CD86, and CD40 in response to NiSO4 or DNCB. CK2 activity also regulated proinflammatory cytokine production, such as TNF-α, IL-1β, and IL-23 in MoDCs. Moreover, in a DC/T cell coculture model in an allogeneic setup, CK2 activity in MoDCs played a major role in Th1 polarization in response to NiSO4 and DNCB. CK2 inhibition in MoDCs led to an enhanced Th2 polarization in the absence of contact sensitizer stimulation.

Consulter en ligne

Suggestions

Du même auteur

Impact of human sequences in variable domains of therapeutic antibodies on the location of CD4 T-cell epitopes

Archive ouverte | Meunier, Sylvain | CCSD

International audience

Specificity of the T Cell Response to Protein Biopharmaceuticals

Archive ouverte | Meunier, Sylvain | CCSD

International audience. The anti-drug antibody (ADA) response is an undesired humoral response raised against protein biopharmaceuticals (BPs) which can dramatically disturb their therapeutic properties. One particu...

Pegylation Reduces the Uptake of Certolizumab Pegol by Dendritic Cells and Epitope Presentation to T-Cells

Archive ouverte | de Bourayne, Marie | CCSD

International audience. Pegylation of biopharmaceuticals is the most common strategy to increase their half-life in the blood and is associated with a reduced immunogenicity. As antigen presentation is a primary eve...

Chargement des enrichissements...